Compare RDCM & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDCM | ENTA |
|---|---|---|
| Founded | 1985 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.2M | 407.5M |
| IPO Year | 1997 | 2013 |
| Metric | RDCM | ENTA |
|---|---|---|
| Price | $13.57 | $15.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $18.00 | ★ $20.40 |
| AVG Volume (30 Days) | 76.8K | ★ 375.0K |
| Earning Date | 11-12-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.57 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $68,901,000.00 | $65,324,000.00 |
| Revenue This Year | $18.86 | $0.99 |
| Revenue Next Year | $11.39 | $0.19 |
| P/E Ratio | $20.99 | ★ N/A |
| Revenue Growth | ★ 17.27 | N/A |
| 52 Week Low | $9.88 | $4.09 |
| 52 Week High | $15.98 | $15.86 |
| Indicator | RDCM | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 68.21 |
| Support Level | $12.81 | $14.07 |
| Resistance Level | $13.88 | $15.28 |
| Average True Range (ATR) | 0.41 | 0.81 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 62.06 | 79.86 |
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.